Rheumatology and immunology research最新文献

{"title":"How will we treat systemic lupus erythematosus in the next 5 years?","authors":"Jiuliang Zhao, Xinping Tian, Mengtao Li, Xiaofeng Zeng","doi":"10.1515/rir-2025-0016","DOIUrl":"10.1515/rir-2025-0016","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"117-119"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The storm inside: Abdominal and urinary complications in lupus.","authors":"Shaoyu Zheng, Guangzhou Du, Yukai Wang","doi":"10.1515/rir-2025-0024","DOIUrl":"10.1515/rir-2025-0024","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"199-201"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495983/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and characteristics of concomitant septic and crystal-induced arthritis: A hospital database and literature review.","authors":"Kittikorn Duangkum, Pattawee Saengmongkonpipat, Pimchanok Tantiwong, Yada Siriphannon, Thida Phungtaharn","doi":"10.1515/rir-2025-0021","DOIUrl":"10.1515/rir-2025-0021","url":null,"abstract":"<p><strong>Background and objectives: </strong>Concomitant septic and crystal-induced arthritis is a rare condition. Failure to diagnose this condition can result in significant harm to the patient. This study aims to investigate the prevalence and characteristics of concomitant septic and crystal-induced arthritis.</p><p><strong>Methods: </strong>A retrospective study included patients diagnosed with concomitant septic and crystal-induced arthritis confirmed by positive bacterial culture and intracellular crystals in synovial fluid of the same joint, from January 1, 2015, to July 31 ,2024.</p><p><strong>Results: </strong>A total of 45 cases were defined as having the prevalence of concomitant septic and crystal-induced arthritis among patients with crystal-induced arthritis of 4% (45/1116). Demographic characteristics showed male predominance (73.3%) with a mean ± SD age of 62.8 ± 14.4 years. Acute monoarthritis (66.7%, <i>n</i> = 30), which primarily affected the knee (68.9%, <i>n</i> = 31), was the most common presentation. Fever was present in 95.6% of cases. The median synovial white blood cell (WBC) count was 61, 478 cells/μL (interquartile range: 33, 600-131, 030). The mean ± SD C-reactive protein (CRP) level was 215 ± 96.7 mg/L. Monosodium urate crystals were found in 80% (<i>n</i> = 36) of the cases. The predominant bacteria were Staphylococcus (48.9%, <i>n</i> = 22), with Methicillin-sensitive <i>Staphylococcus aureus</i> (MSSA) being the most common (28.9%, <i>n</i> = 13), followed by <i>Streptococcus dysgalactiae</i> (15.6%, <i>n</i> = 7) and gram-negative bacilli (15.6%, <i>n</i> = 7). The mortality rate was 15.6% (<i>n</i> = 7).</p><p><strong>Conclusion: </strong>The prevalence of concomitant septic and crystal-induced arthritis was 4% among patients with crystal-induced arthritis, especially among those with acute fever and high synovial WBC counts. The chance of concomitant septic and crystal-induced arthritis is very low in cases with synovial WBC < 12,000 cells/μL.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"179-187"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proceedings of cell-free noncoding RNA biomarker studies in liquid biopsy.","authors":"Yumin Zhu, Fengping Wu, Kangping Liu, Shaozhen Xing, Chun Ning, Meng Ning, Heyue Jin, Yun Shao, Zhenye Zhu, Hongke Wang, Binbin Shi, Yajin Mo, Xinping Tian, Mengtao Li, Jiuliang Zhao, Zhi John Lu, Ning Gu","doi":"10.1515/rir-2025-0018","DOIUrl":"10.1515/rir-2025-0018","url":null,"abstract":"<p><p>Liquid biopsy has great application value in the field of precision medicine because of its non-invasiveness, sensitivity and dynamics. Cell-free RNA molecules are one of the emerging biomarkers that can be used for liquid biopsy, and cell-free non-coding RNAs have become main RNA molecular markers because of their high abundance and stability, as well as their regulatory roles in basic development. It provides clues for the diagnosis, prognosis and monitoring of a variety of complex diseases, including rheumatic and immune diseases. This article describes the characterization of cell-free non-coding RNAs and bioinformatics strategies, and summarizes cell-free non-coding RNA biomarkers associated with rheumatic and immune diseases. Prospects and reflections are made on the further research and clinical application of cell-free RNA markers.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"149-158"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating risk assessment in connective tissue disease-associated pulmonary arterial hypertension: The prognostic superiority of stroke volume index.","authors":"Qingqing Cai, Huangshu Ye, Yixin Zhang, Jiayi Dai, Linwei Shan, Zhangdi Zhou, Dongyu Li, Ting Liu, Yanli Zhou, Fenghong Yuan, Xiaoxuan Sun","doi":"10.1515/rir-2025-0020","DOIUrl":"10.1515/rir-2025-0020","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the prognostic value of stroke volume index (SVI) compared to cardiac index (CI) in risk stratification and outcome prediction in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).</p><p><strong>Methods: </strong>We performed a retrospective analysis of patients diagnosed with CTD-PAH through right heart catheterization (RHC) from two Chinese medical centers. This retrospective study analyzed 206 CTD-PAH patients, with risk stratification performed using the 2018 World Symposia on Pulmonary Hypertension (WSPH) framework. Restricted cubic splines (RCS) and log-rank tests were utilized to identify the optimal SVI cutof values for categorizing patients into low-, intermediate-, and high-risk groups. Kaplan-Meier (KM) curves were used to analyze survival rates and event-free survival. Receiver operating characteristic (ROC) analysis was used to assess the predictive accuracy of diferent models for prognostic outcomes.</p><p><strong>Results: </strong>SVI was categorized into low-risk (SVI ≥ 33.35 mL/m²), intermediate-risk (24.66 mL/m²≤ SVI < 33.35 mL/m²), and high-risk (SVI < 24.66 mL/m²) groups. Among the 206 CTD-PAH patients, 55 exhibited discrepancies in risk stratification between CI and SVI. SVI-based stratification provided more accurate risk categorization and demonstrated superior predictive value compared to CI, showing significant diferences in both survival and event-free survival rates across the groups.</p><p><strong>Conclusion: </strong>SVI enhances risk stratification and prognosis prediction in CTD-PAH by efectively distinguishing patients at higher risk for adverse outcomes.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"168-178"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2025 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus.","authors":"Jiuliang Zhao, Shangzhu Zhang, Qian Wang, Xinping Tian, Yaolong Chen, Mengtao Li, Xiaofeng Zeng","doi":"10.1515/rir-2025-0017","DOIUrl":"10.1515/rir-2025-0017","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a complex autoimmune disease that poses significant challenges in diagnosis and treatment. In recent years, advances in basic and clinical research related to SLE have led to the emergence of new diagnostic and therapeutic approaches, as well as the continuous updates of international clinical guidelines. Consequently, existing guidelines no longer fully align with current clinical practice in China. Initiated by the National Clinical Research Center for Dermatologic and Immunologic Diseases and the Chinese SLE Treatment and Research Group, and in collaboration with the Chinese Rheumatology Association and Chinese Association of Rheumatology and Immunology Physicians, an expert panel has comprehensively evaluated the latest research evidence and integrated domestic clinical experience. In accordance with the GRADE framework, the \"2020 Chinese Guidelines for the Diagnosis and Treatment of Systemic Lupus Erythematosus\" have undergone systematic revision. The updated guidelines provide detailed evidence-based recommendations addressing 12 critical clinical concerns prioritized by frontline rheumatologists in China. The revision aims to optimize the scientific rigor of SLE clinical management and enhance patient-centered healthcare services.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"120-148"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of <i>HLA-B</i> and <i>HLA-DR</i> gene polymorphisms with rheumatoid arthritis: A cross-sectional study in Yunnan Chinese Han population.","authors":"Jing Dong, Yifan Yang, Minghuang Mo, Shuang Liu, Ru Bai, Shu Li, Ruotong Zhao, Xinyu Xu, Yuqi Cheng, Jian Xu","doi":"10.1515/rir-2025-0022","DOIUrl":"10.1515/rir-2025-0022","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association between <i>HLA-B</i> and <i>HLA-DR</i> gene polymorphisms and rheumatoid arthritis (RA) in Yunnan Han population, China.</p><p><strong>Methods: </strong>A total of 246 RA patients and 259 healthy controls (HCs) were enrolled. <i>HLA-B/DR</i> genotyping was performed using high-resolution reverse polymerase chain reaction sequence specific oligonucleotide probe (PCR-SSOP). and serum anti cyclic citrullinated peptide (anti-CCP) antibody and serological indexes were detected.</p><p><strong>Results: </strong>In RA patients, the allele frequencies of <i>HLA-DRB1*04:05:01</i>, <i>*04:10:01</i>, <i>*10:01:02</i> and <i>HLA-B*15:01:01G</i>, <i>*40:01:01G</i>, <i>*40:02:01G</i>, and <i>*54:01:01G</i> were significantly higher than those in the HCs (OR > 1, all <i>P</i> < 0.05). Conversely, the frequencies of <i>HLA-DRB1*07:01:01</i>, <i>*14:01:01</i>, <i>*15:01:01:01</i> and <i>HLA-B*15:01:01</i>, <i>*15:02:01</i>, and <i>*38:02:01</i> alleles were decreased in RA group (OR < 1, all <i>P</i> < 0.05). Haplotype analysis showed that the combination of <i>HLA-B*15:01/DRB1*09:01</i>, <i>HLA-B*38:02/DRB1*08:03</i> and <i>HLA-B*54:01/DRB1*04:05</i> was decreased in RA patients (OR < 1, all <i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>The susceptibility of RA in Yunnan Han population is closely related to HLA-B/DR specific alleles and haplotypes.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 3","pages":"188-194"},"PeriodicalIF":2.5,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tadalafil plus endothelin receptor antagonists in connective tissue disease-associated pulmonary arterial hypertension: A multicenter study on exercise capacity and cardiac outcomes.","authors":"Qianwen Wu, Hua Ma, Dongyu Li, Huangshu Ye, Zhangdi Zhou, Ning Zhang, Yinsu Zhu, Ting Liu, Xiaoxuan Sun, Miaojia Zhang, Qiang Wang","doi":"10.1515/rir-2025-0012","DOIUrl":"10.1515/rir-2025-0012","url":null,"abstract":"<p><strong>Background and objectives: </strong>Pulmonary arterial hypertension (PAH) is a life-threatening condition that requires optimized medical therapy to maintain a low-risk profile. This study assessed the effects of initial PAH-specific combination therapy with tadalafil/sildenafil on clinical and functional outcomes in a real-world setting.</p><p><strong>Methods: </strong>We conducted a multicenter retrospective study of 85 patients diagnosed with connective tissue disease-associated PAH (CTD-PAH) <i>via</i> right heart catheterization from 2009 to 2023. Data on treatment regimens and efficacy measures, including 6-min walk distance (6MWD), N-terminal pro-B-type natriuretic peptide (NT-pro BNP), soluble suppression of tumorigenicity 2 (sST2), World Health Organization (WHO) functional class, risk stratification, treat-to-target status and survival, were collected.</p><p><strong>Results: </strong>Patients receiving initial combination therapy with endothelin receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors showed varied improvements. The tadalafil plus ERAs combination significantly reduced NT-pro BNP levels and improved risk status (<i>P</i> < 0.05). Notable enhancements in 6MWD, soluble ST2, and WHO functional class were observed in the tadalafil plus ERA group (<i>P</i> < 0.001), but not in the sildenafil group (<i>P</i> > 0.05). Additionally, 1-year treat-to-target rates were higher in the tadalafil plus ERA group (73.5%) than in the sildenafil group (45.6%, <i>P</i> = 0.005).</p><p><strong>Conclusion: </strong>These findings suggest that tadalafil combined with ERAs leads to better improvements in exercise capacity, functional class, and treatment goals compared to sildenafil-based regimens, offering valuable insights for optimizing CTD-PAH treatment.</p>","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 2","pages":"90-98"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated.","authors":"Giulia Micheli, Lorenzo Salvati, Boaz Palterer, Emanuele Vivarelli, Alessio Mazzoni, Nila Volpi, Alessandra Vultaggio, Andrea Matucci, Lorenzo Cosmi, Daniele Cammelli, Paola Parronchi","doi":"10.1515/rir-2025-0014","DOIUrl":"10.1515/rir-2025-0014","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 2","pages":"110-113"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medusas petrifying gaze: Severe, diffused and refractory calcinosis from a patient with ACA-negative CREST syndrome.","authors":"Lili Xu, Jie Wu, Shu Liang, Yilin Lu, Yilu Qin, Chao Zhang, Miaomiao Ma, Wenqiang Fan","doi":"10.1515/rir-2025-0015","DOIUrl":"10.1515/rir-2025-0015","url":null,"abstract":"","PeriodicalId":74736,"journal":{"name":"Rheumatology and immunology research","volume":"6 2","pages":"114-116"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12212630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144556123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}